Treating Multidrug-Resistant Tuberculosis

Treating Multidrug-Resistant Tuberculosis

Multidrug-resistant tuberculosis, resistant to isoniazid and rifampin, is diagnosed in almost half-a-million new people each year. The World Health Organization recommends a 20-month treatment course, but cohort studies in Bangladesh have shown promising results in multidrug-resistant tuberculosis using shorter regimens. This randomized, noninferiority trial of participants with rifampin-resistant TB susceptible to fluoroquinolones and aminoglycosides compared

Read More